Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025; In parallel, the Company continues to analyze data and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback